The FDA approved an allogeneic cord-blood-based cell therapy for people with blood cancers.

The American Hospital Association teamed up with nonprofit organization 340B Health and the Arkansas Hospital Association to file an amicus brief against a constitutional challenge brought by a pharma lobby group. 

So far in April, seven more drugs are in short supply and six are discontinued, according to the FDA and the American Society of Health-System Pharmacists.

For decades, cancer vaccines have been tested, though no real promising results have emerged. However, results of a new clinical trial involving melanoma patients are giving experts a fresh boost of optimism. 

HHS is planning to extend certain flexibilities and liability protections for pharmacy workers under the Public Readiness and Emergency Preparedness Act until December 2024, the agency said April 14.

In the middle of a rising wave of strep cases and an ongoing nationwide shortage of amoxicillin that normally treats it, a Wisconsin pharmacist is finding ways to make ends meet, ABC News affiliate WKOW reported April 12.

Pharmacies earned a record $548 billion from prescription dispensing revenues in 2022, and 15 pharmacies account for 75 percent of that figure, according to Drug Channels.

Two gene therapies for sickle cell disease are each worth up to $1.9 million, according to an April 12 draft evidence report from the Institute for Clinical and Economic Review.

Horizon Therapeutics, a biopharmaceutical company focusing on treatments for rare diseases, has a unique success story, considering the company hasn't licensed a single drug product since its founding in 2008, KFF Health News reported April 13.

Payer- and pharmacy benefit manager-owned specialty pharmacy chains displaced retail chains as the most lucrative specialty pharmacy businesses in 2022, according to Drug Channels. 

Walgreens and healthcare coaching company Cariloop are teaming up to help multiple sclerosis patients and their caregivers. 

Ten months after Moderna announced its phase 3 trial for a flu shot candidate, the company says the vaccine "did not accrue sufficient cases in an early efficacy analysis" to declare success.

The Biden administration designated fentanyl-xylazine combinations as an "emerging threat" April 12.  

Cambridge, Mass.-based Biogen is cutting its workforce again after laying off 885 people last year, Boston Business Journal reported April 10.

Thirty-four solutions of docetaxel injection, a drug intended for five different cancers, are on back order, according to the American Society of Health-System Pharmacists.

The FDA included quinacrine hydrochloride to its list of bulk drug substances allowed to be used in compounding by outsourcing facilities on April 6. It is the fifth addition and is for oral use only. 

Two drugmakers withdrew two indications for their drug Imbruvica (ibrutinib) — the treatment for mantle cell lymphoma and marginal zone lymphoma — after a failure to meet endpoints in a phase 3 study. 

Expanded reimbursement for pharmacist services is something industry professionals and organizations like the American Society of Health-System Pharmacists have long advocated for, but it can be complex to execute, researchers have said. But since 2023, several states have passed legislation broadening the scope for such.

The FDA withdrew its approval of Makena, the only preterm birth drug greenlit by the agency, on April 6 after research showed the treatment did not work better than a placebo. 

Camber Pharmaceuticals recalled one lot of a drug for pneumocystis jiroveci pneumonia because of the contamination risk of Bacillus cereus.